📰 Nasdaq Mack News
Nasdaq Mack News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Mack. Real-time updates on events, politics, business and more.
February 1, 2024
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK – Get Free Report) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $12.55 and traded as high as $13.47. Merrimack Pharmaceuticals shares last traded at $13.44, with a volume of 29,917 shares traded. Analysts Set New Price Targets Separately, StockNews.com […]
January 27, 2024
Merrimack Pharmaceuticals (NASDAQ:MACK – Get Free Report) and Cellectar Biosciences (NASDAQ:CLRB – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, analyst recommendations and institutional ownership. Earnings & Valuation This table compares Merrimack […]
January 27, 2024
StockNews.com lowered shares of Merrimack Pharmaceuticals (NASDAQ:MACK – Free Report) from a hold rating to a sell rating in a report issued on Tuesday. Merrimack Pharmaceuticals Stock Down 0.4 % MACK stock opened at $13.25 on Tuesday. The business has a fifty day moving average of $13.10 and a two-hundred day moving average of $12.52. […]
January 5, 2024
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK – Get Free Report) shares passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $12.40 and traded as high as $13.39. Merrimack Pharmaceuticals shares last traded at $13.32, with a volume of 36,749 shares. Analyst Ratings Changes Separately, StockNews.com upgraded shares […]
December 14, 2023
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK – Get Free Report) Director Eric Andersen bought 101,050 shares of the company’s stock in a transaction that occurred on Thursday, December 7th. The stock was bought at an average cost of $12.85 per share, for a total transaction of $1,298,492.50. Following the completion of the transaction, the director now directly […]
August 18, 2023
StockNews.com began coverage on shares of Merrimack Pharmaceuticals (NASDAQ:MACK – Free Report) in a research note issued to investors on Thursday. The firm issued a sell rating on the biopharmaceutical company’s stock. Merrimack Pharmaceuticals Trading Up 1.5 % NASDAQ MACK traded up $0.18 on Thursday, hitting $12.19. 26,084 shares of the company’s stock traded hands, […]
August 14, 2023
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK – Get Free Report) insider Gary L. Crocker purchased 2,000 shares of the business’s stock in a transaction on Thursday, August 10th. The stock was bought at an average cost of $12.52 per share, with a total value of $25,040.00. Following the purchase, the insider now owns 133,105 shares in the […]
August 9, 2023
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK – Get Free Report) Director Eric Andersen acquired 134,493 shares of the company’s stock in a transaction that occurred on Monday, August 7th. The shares were acquired at an average cost of $12.00 per share, for a total transaction of $1,613,916.00. Following the purchase, the director now directly owns 1,496,680 shares […]
July 8, 2023
Merrimack Pharmaceuticals (NASDAQ:MACK – Free Report) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a report released on Friday. Merrimack Pharmaceuticals Price Performance Shares of MACK stock traded down $0.08 during trading hours on Friday, reaching $11.80. 209,960 shares of the stock were exchanged, compared to its average volume of […]
June 1, 2023
Merrimack Pharmaceuticals (NASDAQ:MACK – Get Rating) and Rallybio (NASDAQ:RLYB – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends and valuation. Volatility & Risk Merrimack Pharmaceuticals has a beta of 1.84, […]